Nuclear-level dimensionality reduction strike! AI + DeSci develops drugs in just 24 hours at a cost of only $600, collapsing traditional pharmaceutical R&D systems costing millions of dollars! Is the next hundredfold opportunity for retail investors right here?

Bro, sit down, I have something to tell you. — Last weekend, the CEO of the DeSci funding platform Bio Protocol personally admitted that their AI team designed a new candidate drug for ADHD (Attention Deficit Hyperactivity Disorder) in just one day, about 24 hours.

The AI scientist called PeptAI in the team threw the candidate into a simulated testing pipeline and honestly pointed out what issues this thing might face in the real world. The cost of the first physical laboratory test was set between $500 and $600. Full validation, all steps completed, roughly $1,000 to $1,500.

Guess how much traditional pharmaceutical companies spend to reach the same decision point? Millions of dollars. Time? Several years. Not tens of thousands, but millions. Not a few months, but years.

This is what the hell is called “complexity collapse”—previously, the decision about which diseases to research and which questions to raise was firmly in the hands of capital, with little to do with science itself. Research only gets funded if it aligns with commercial priorities or hits “hot” topics. Many valuable fields, like rare diseases or non-mainstream mechanisms, are completely ignored.

DeSci (Decentralized Science) has been trying to fill this funding gap in recent years, but the entire ambition has been held back by the high costs of drug discovery itself. Think about it: even if a DAO has strong community fundraising ability, facing R&D costs of tens of millions can only leave them staring blankly.

Now, things have changed. AI has flipped the script on mathematical calculations, driving R&D costs down to rock-bottom prices. When costs drop to a few hundred dollars, DAO funds can fully support candidate drugs until they get real lab data. Those research areas that pharmaceutical companies once looked down on—like the biological mechanisms behind the appetite system in ADHD—researchers have studied for years, but no drug company was willing to fund development. Now, PeptAI has chosen it, and it only took a weekend.

Bio Protocol plays a key role here. It’s a token-governed platform where the community votes to allocate funds to specialized research DAOs. Over the past few months, it has also been making rapid advances in intelligent agent science. PeptAI’s success with OX2R-004 is just the latest example, not an isolated case. In January this year, the team released BIOS, an AI scientist dedicated to coordinating specialized intelligent agents for literature searches and computational analysis.

The key is that Bio Protocol runs two engines simultaneously: community fundraising and intelligent agent science. The two are highly coordinated—if AI can design candidates at sufficiently low costs, allowing the community to directly fund them, then the earliest stages of drug discovery no longer need to rely on institutional gatekeeping.

But don’t rush to go all-in. Bio Protocol itself is very transparent that AI and community funding still face three structural issues. They clearly stated this in a recent post.

First, data inaccessibility. The data used to train AI models to simulate in vivo drug behavior are locked in pharmaceutical companies’ vaults—collected over decades and regarded as core competitive weapons, making them impossible to access.

Second, laboratory environment. Testing compounds requires physical space, biological materials, and weeks of contracts and coordination. No AI can eliminate this physical step.

Third, clinical trials. The stage where candidate drugs are tested on humans still operates within the old capital structure. The DeSci stack currently has nothing to reach this level.

However, a cultural shift worth noting is underway. The rise of peptide culture, GitLab co-founder Sid Sijbrandij using AI to fight his own cancer, Australian tech entrepreneur Paul Conyngham using ChatGPT to treat his dog Rosie’s cancer—these stories point to a growing community driven more by personal stakes than by commercial motives.

Clinical validation remains important, and doctors are still crucial. But what’s changing is that those motivated to ask new questions now have tools to bring those questions into real scientific answers at extremely low costs.

Obstacles to reaching the finish line still exist. After lab validation, there are preclinical safety tests ($500k to $2 million), then submitting IND applications to the FDA, followed by three phases of clinical trials, costing tens of millions to hundreds of millions of dollars. But DeSci can now bring a real data package to the start of this path—a compound with published, linked data, and every decision permanently recorded on the chain. This is a completely different level from the previous starting point, which was just a hypothesis and a funding proposal.

The entire scope of the research field is being redefined. Diseases that traditional pharma companies ignored due to rarity, lack of profit, or non-traditional science now have a clear, low-cost validation path.

This undercurrent is already perceptible and will only grow stronger.

(Note: The DeSci-related project token $BIO has recently been listed on multiple exchanges, and market sentiment is reacting positively to the AI + DeSci narrative.)

Follow me: for more real-time analysis and insights into the crypto market! $BTC $ETH $SOL

#WCTC交易王PK #Crypto market volatility #rsETH attack follow-up